Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
21.56 AUD | +6.73% | +7.46% | -13.50% |
05-09 | Neuren Pharmaceuticals Partner Acadia Pharmaceuticals Posts US DAYBUE Sales of $75.9 Million | MT |
04-24 | Neuren Pharmaceuticals Posts AU$243 Million Cash, Short-Term Investments | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.50% | 1.61B | |
+31.06% | 682B | |
+30.35% | 586B | |
-3.42% | 364B | |
+18.02% | 327B | |
+4.27% | 285B | |
+15.53% | 240B | |
+10.16% | 209B | |
-8.14% | 203B | |
+8.12% | 165B |
- Stock Market
- Equities
- NEU Stock
- News Neuren Pharmaceuticals Limited
- Transcript : Neuren Pharmaceuticals Limited, Q4 2023 Earnings Call, Feb 29, 2024